Virtus LifeSci Biotech Products ETF (BBP)

NYSEARCA: BBP · Real-Time Price · USD
63.21
-0.79 (-1.24%)
Jul 24, 2025, 4:00 PM - Market closed
-1.24%
Assets$24.67M
Expense Ratio0.79%
PE Ration/a
Shares Out400,004
Dividend (ttm)n/a
Dividend Yieldn/a
Ex-Dividend Daten/a
Payout Frequencyn/a
Payout Ration/a
Volume1,959
Open63.86
Previous Close64.00
Day's Range62.67 - 63.86
52-Week Low48.65
52-Week High69.12
Beta0.53
Holdings57
Inception DateDec 17, 2014

About BBP

Fund Home Page

The Virtus LifeSci Biotech Products ETF (BBP) is an exchange-traded fund that is based on the LifeSci Biotechnology Products index. The fund tracks an index of US-listed biotechnology companies considered to be in the product stage by the index provider. BBP was launched on Dec 17, 2014 and is issued by Virtus Investment Partners.

Asset Class Equity
Category Health
Region North America
Stock Exchange NYSEARCA
Ticker Symbol BBP
Index Tracked LifeSci Biotechnology Products Index

Top 10 Holdings

22.25% of assets
NameSymbolWeight
CRISPR Therapeutics AGCRSP2.84%
Rhythm Pharmaceuticals, Inc.RYTM2.47%
Iovance Biotherapeutics, Inc.IOVA2.41%
Moderna, Inc.MRNA2.13%
Ardelyx, Inc.ARDX2.11%
Ionis Pharmaceuticals, Inc.IONS2.09%
Legend Biotech CorporationLEGN2.06%
Ligand Pharmaceuticals Inc.LGND2.06%
BridgeBio Pharma, Inc.BBIO2.05%
Agios Pharmaceuticals, Inc.AGIO2.04%
View More Holdings

Performance

BBP had a total return of -1.24% in the past year, including dividends. Since the fund's inception, the average annual return has been 9.24%.

Chart

Bar chart with 6 bars.
The chart has 1 X axis displaying categories.
The chart has 1 Y axis displaying values. Data ranges from -1.2356249999999958 to 9.235.
End of interactive chart.

News

Healthcare Sector Checkup As U.S. Looks To Change Regulations

Outlook for pharma sector as Trump pushes for regulatory changes. The impact of tariffs on drugmakers.

7 weeks ago - Seeking Alpha

Seeking Stocks With Vitality In The Volatile Healthcare Sector

Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US admini...

5 months ago - Seeking Alpha

Can Health Care Stocks Outperform Again In 2023?

How a recession could impact health care stocks in 2023. As Covid continues, what it could mean for the health care sector.

2 years ago - Seeking Alpha

Biotechs Ready To Roar

Biotechs are ready to march forcefully higher after a lengthy consolidation. Approval of Biogen's Alzheimer's treatment creates a bonanza for neurodegenerative-focused companies and the overall biotec...

4 years ago - Seeking Alpha

Biotech Innovations Remain At Forefront

The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively r...

4 years ago - Seeking Alpha

Moving Beyond COVID In Biopharma

Just over one year after COVID-19 disrupted our lives, we are now getting to the point where multiple vaccine options are nearly ubiquitous for those in the United States. Per the CDC, as of April 12,...

4 years ago - Seeking Alpha

Late-stage biotech ETFs rally Monday on virus treatment hopes

Late-stage biotech exchange-traded funds were among the day's biggest gainers Monday as investors pinned their hopes on medical responses to the novel coronavirus. The ALPS Medical Breakthroughs ETF ...

Other symbols: SBIO
5 years ago - Market Watch